Response to Pazopanib in Two Pediatric Patients with Pretreated Relapsing Synovial Sarcoma

2017 ◽  
Vol 103 (1) ◽  
pp. e1-e3 ◽  
Author(s):  
Michela Casanova ◽  
Eleonora Basso ◽  
Chiara Magni ◽  
Luca Bergamaschi ◽  
Stefano Chiaravalli ◽  
...  

Pazopanib is an oral multikinase inhibitor that has proved effective in adults treated for relapsing soft tissue sarcoma and synovial sarcoma in particular. Two cases are reported here of pediatric patients with pretreated relapsing synovial sarcoma whose tumors showed a prolonged response to pazopanib given on compassionate grounds. These results suggest that new agents found effective in adult patients might achieve similar results in adolescents with the same disease. Facilitating the availability of new drugs for children and adolescents is a major challenge for pediatric oncologists.

2015 ◽  
Vol 26 (3) ◽  
pp. 567-572 ◽  
Author(s):  
A. Ferrari ◽  
G.L. De Salvo ◽  
B. Brennan ◽  
M.M. van Noesel ◽  
A. De Paoli ◽  
...  

2016 ◽  
Vol 69 (5) ◽  
pp. 792-801 ◽  
Author(s):  
Wan-Shan Li ◽  
I-Chuang Liao ◽  
Mei-Chin Wen ◽  
Howard Haw-Chang Lan ◽  
Shih-Chen Yu ◽  
...  

2018 ◽  
Author(s):  
Robert J Canter

Although neoadjuvant chemotherapy has been an established component of multimodality cancer care for patients with pediatric sarcomas for the past 25 years, the role of adjuvant or neoadjuvant chemotherapy in the management of adult patients with soft tissue sarcoma (STS) amenable to treatment with curative intent remains controversial. Overall, meta-analyses have revealed modest improvements in survival outcomes with the use of adjuvant or neoadjuvant chemotherapy, but individual trials have demonstrated inconsistent results leading some to question the robustness and external validity of the results. A recent randomized trial using anthracycline- and ifosfamide-based chemotherapy has provided further positive evidence in support of neoadjuvant chemotherapy for adult STS patients, but concerns persist regarding the risks of chemotherapy-related toxicities and the generalizability of the findings. Given the substantial risk of distant recurrence and disease-specific death for adult STS patients with tumors greater than 10 cm, especially those with synovial sarcoma and myxoid or round liposarcoma histologies, these patients should be strongly considered for neoadjuvant chemotherapy as part of a combined modality approach. The impact of recent level I data on the broader implementation of adjuvant or neoadjuvant chemotherapy in adult STS remains to be seen.  This review contains 5 figures and 34 references Key Words: chemotherapy, limb salvage, myxoid/round cell liposarcoma, multimodality therapy, soft tissue sarcoma, surgery, survival, synovial sarcoma, undifferentiated pleomorphic sarcoma  


BMC Cancer ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Fernando A. Angarita ◽  
Amanda J. Cannell ◽  
Albiruni R. Abdul Razak ◽  
Brendan C. Dickson ◽  
Martin E. Blackstein

Sign in / Sign up

Export Citation Format

Share Document